We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




An Aptamer-Liposome Delivery System Targets Breast Cancer Cells

By LabMedica International staff writers
Posted on 18 Aug 2009
A specific and reversible drug delivery system has been constructed from liposomes bound to specific aptamers, which are short strands of DNA or RNA.

Investigators at the University of Illinois (Champaign-Urbana, USA) encapsulated the chemotherapeutic drug cisplatin into phospholipid liposomes. More...
The liposomes were tagged with DNA aptamers that bound specifically to nucleolin receptors, which are found in abundance on certain breast cancer cells.

The cisplatin-liposomes were used to treat breast cancer cells growing in tissue culture. Results published in the July 21, 2009 online edition of the journal Angewandte Chemie revealed that by four days after liposome treatment 59.5% of the breast cancer cells had died, while less than 12% of breast cancer cells treated with cisplatin alone had died.

Senior author Dr. Yi Lu, professor of chemistry at the University of Illinois, said, "By labeling a liposome that contains cisplatin with a cancer cell-specific aptamer, we have shown delivery of the drugs to cancer cells without significant damage to regular cells, making it possible to maximize the drug potency while minimizing its side effects.”

The investigators also reported that by adding a complimentary aptamer that would bind to and neutralize the cancer specific aptamer attached to the liposomes they could regulate the effective dosage of chemotherapeutic agent.

Related Links:

University of Illinois




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.